Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and
efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in
postmenopausal patients with primary breast cancer.
This trial is not recruiting patients in the United States.